Agenus (NASDAQ:AGEN – Get Free Report) is expected to be releasing its earnings data before the market opens on Tuesday, March 11th. Analysts expect Agenus to post earnings of ($2.36) per share and revenue of $30.09 million for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.
Agenus Stock Performance
NASDAQ AGEN opened at $2.35 on Monday. The business’s fifty day moving average is $3.27 and its 200 day moving average is $3.90. Agenus has a fifty-two week low of $2.31 and a fifty-two week high of $19.69. The company has a market capitalization of $55.13 million, a PE ratio of -0.21 and a beta of 1.23.
Analyst Ratings Changes
Separately, HC Wainwright restated a “neutral” rating on shares of Agenus in a research report on Wednesday, January 22nd. One analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $10.00.
About Agenus
Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Featured Stories
- Five stocks we like better than Agenus
- What is Forex and How Does it Work?
- Institutional Investors Bet $1B on These 4 Stocks—Should You?
- How to Invest in the Best Canadian Stocks
- One Must-Buy Stock and One to Avoid as Tariffs Shake the Market
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.
